Confocal Laser Endomicroscopy for the Detection of Gastric Intestinal Metaplasia: a Randomized Controlled Trial
Comparison of Confocal Laser Endomicroscopy With Standard Endoscopy for the Detection and Evaluation of Gastric Intestinal Metaplasia in a High Risk Population: A Randomized Controlled Trial
1 other identifier
interventional
168
1 country
1
Brief Summary
The purpose of this study is to assess whether confocal laser endomicroscopy can reduce the biopsy number needed per patient for the detection of gastric intestinal metaplasia without the loss of corresponding diagnostic yield.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2009
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 2, 2009
CompletedFirst Posted
Study publicly available on registry
December 3, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2010
CompletedJuly 17, 2012
July 1, 2012
7 months
December 2, 2009
July 16, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the diagnostic yield of gastric intestinal metaplasia
Seven months
Secondary Outcomes (1)
the biopsy number needed in each group
Seven months
Study Arms (2)
1
EXPERIMENTALconfocal laser endomicroscopy
2
ACTIVE COMPARATORstandard endoscopy
Interventions
Pentax EG-2931 gastroscope
Eligibility Criteria
You may qualify if:
- years old ≤ age \< 80 years old
- Patients with dyspeptic symptoms and/or with certain risk factors of gastric intestinal metaplasia
- Able to give informed consent.
You may not qualify if:
- Esophageal, gastric or duodenal cancer or other malignancy
- Known GIM or intraepithelial neoplasia in upper GI tract
- Scheduled for endoscopic therapy
- History of upper GI tract surgery
- Reflux esophagitis or acute gastritis or peptic ulcers
- Acute upper gastrointestinal bleeding
- Coagulopathy or bleeding disorders
- Allergy to fluorescein sodium
- Pregnant or breast-feeding (for females)
- Impaired renal function
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Gastroenterology, Qilu Hospital, Shandong University
Jinan, Shandong, 250012, China
Study Officials
- STUDY DIRECTOR
Yanqing Li, PhD. MD.
Department of Gastroenterology, Qilu Hospital, Shandong University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of the Department of Gastroenterolgoy, Qilu Hospital
Study Record Dates
First Submitted
December 2, 2009
First Posted
December 3, 2009
Study Start
November 1, 2009
Primary Completion
June 1, 2010
Study Completion
July 1, 2010
Last Updated
July 17, 2012
Record last verified: 2012-07